Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1005 | 1040 | 1006 | 1221 | 1267 | 1778 |
Fund Return | 0.52% | 3.98% | 0.63% | 6.88% | 4.85% | 5.93% |
Place in category | 104 | 253 | 175 | 89 | 95 | 29 |
% in Category | 23 | 61 | 43 | 22 | 29 | 12 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Liontrust Special Situations Fund R | 34.41M | -1.48 | 2.55 | 6.09 | ||
Liontrust Special Situations Fund A | 5.41M | 4.82 | 0.46 | 7.81 | ||
Liontrust Special Situations Fund I | 2.31B | 1.91 | -0.48 | 7.96 | ||
Liontrust European Growth Fund A In | 9.12M | 5.45 | 9.06 | 11.93 | ||
Liontrust European Growth Fund I In | 660.45M | 2.40 | 7.05 | 11.81 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Liontrust Special Situations Fund R | 34.41M | -1.48 | 2.55 | 6.09 | ||
Liontrust Special Situations Fund A | 5.41M | 4.82 | 0.46 | 7.81 | ||
Liontrust Special Situations Fund I | 2.31B | 1.91 | -0.48 | 7.96 | ||
Artemis UK Select Fund R Acc | 208.66M | 19.01 | 7.59 | 8.68 | ||
Artemis UK Select Fund I Inc GBP | 171.47M | 19.77 | 8.40 | 9.32 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Shell | GB00BP6MXD84 | 8.31 | 30.72 | -0.52% | |
AstraZeneca | GB0009895292 | 7.59 | 10,532.0 | +0.38% | |
BP | GB0007980591 | 5.63 | 384.15 | +0.18% | |
Unilever | GB00B10RZP78 | 4.75 | 56.74 | +1.00% | |
GSK plc | GB00BN7SWP63 | 4.67 | 1,344.00 | +0.45% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Buy | Buy | Strong Buy |
Technical Indicators | Strong Buy | Sell | Strong Buy |
Summary | Strong Buy | Neutral | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review